Clinical significance of α-Catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer

Journal of Clinical Oncology

Volumn 16, Issue 8, 1998, Pages 2591-2600

  Anttila, Maarit ^a   Kosma, Veli Matti ^a   Ji, Hongxiu ^a   Wei Ling, Xu ^a   Puolakka, Jukka ^a   Juhola, Matti ^a   Saarikoski, Seppo ^a   Syrjänen, Kari ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CATENIN; COLLAGEN TYPE 4; KI 67 ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS;

EID: 0031904555     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.8.2591     Document Type: Article

References (58)

1. Cannistra SA: Cancer of the ovary. N Engl J Med 329:1550-1557, 1993
2. Smith EM, Anderson B: The effects of symptoms and delay in seeking diagnosis on stage of disease at diagnosis among women with cancers of the ovary. Cancer 56:2727-2732, 1985
3. Saigo PE: The histology of malignant ovarian tumors, in Markman M, Hoskin WJ (eds): Cancer of the ovary. New York, NY, Raven, 1993, pp 21-46
4. Martinez-Hernandez A, Amenta PS: The basement membrane in pathology. Lab Invest 48:656-677, 1983
5. Liotta LA: Tumor invasion and metastases: Role of the basement membrane. Am J Pathol 117:339-348, 1984
6. Barsky SH, Siegal GP, Jannotta F, et al: Loss of basement membrane components by invasive tumors but not with their benign counterparts. Lab Invest 49:140-147, 1983
7. Havenith MG, Arenas JW, Simon R, et al: Type IV collagen immunoreactivity in colorectal cancer: Prognostic value of basement membrane deposition. Cancer 62:2207-2211, 1988
8. Daher N, Abourachid H, Bove N, et al: Collagen IV staining pattern in bladder carcinomas: Relationship to prognosis. Br J Cancer 55:665-671, 1987
9. Bremer GL, Tiebosch ATMG, van der Putten HWHM, et al: Basement membranes in cervical cancer: Relationship to pelvic lymph node metastasis and prognosis. Gynecol Oncol 57:351-355, 1995
10. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251:1451-1455, 1991
11. Takeichi M: Cadherins in cancer: Implications for invasion and metastasis. Curr Opin Cell Biol 5:806-811, 1993
12. Hashimoto M, Niwa O, Nitta Y, et al: Unstable expression of E-cadherin adhesion molecules in metastatic ovarian tumor cells. Jpn J Cancer Res 80:459-463, 1989
13. Hoffman AG, Burghart RC, Tilley R, et al: An in vitro model of ovarian epithelial carcinogenesis: Changes in cell-cell communication and adhesion occurring during neoplastic progression. Int J Cancer 54:828-838, 1993
14. Inoue M, Ogawa H, Miyata M, et al: Expression of E-cadherin in normal, benign, and malignant tissues of female genital organs. Am J Clin Pathol 98:76-80, 1992
15. Sakuragi N, Nishiya M, Ikeda K, et al: E-cadherin expression in endometrial carcinoma is associated with tumor dedifferentiation and deep myometrial invasion. Gynecol Oncol 53:183-189, 1994
16. Peyrieras N, Louvard D, Jacob F: Characterization of antigens recognized by monoclonal and polyclonal antibodies directed against uvomorulm. Proc Natl Acad Sci USA 82:8067-8071, 1982
17. Hirano S, Kimoto N, Shimoyama Y, et al: Identification of neural α-catenin as a key regulator of catenin function and multicellular organization. Cell 70:293-301, 1992
18. Kadowaki T, Shiozaki H, Inoue M, et al: E-cadherin and a-catenin expression in human esophageal cancer. Cancer Res 54:291-296, 1994
19. HashizumeR, Koizumi H, Ihara A, et al: Expression of β-catenin in normal breast tissue and breast carcinoma: A comparative study with epithelial cadherin and α-catenin. Histopathology 29:139-146, 1996
20. Hall Pa, Levison DA: Review: Assessment of cell proliferation in histological material. J Clin Pathol 43:184-192, 1990
21. Cancer Committee of the International Federation of Gynecology and Obstetrics: Staging Announcement: FIGO Cancer Committee. Gynecol Oncol 25:383-385, 1986
22. Serov SF, Scully RE, Sobin LH: International Histologic Classification and Staging of Tumors. No. 9 Histologic Typing of Ovarian Tumors. Geneva, Switzerland, World Health Organization, 1973
23. Garzetti GG, Ciavattini A, Gotteri G, et al: Ki 67 immunostaining (MIB1 monoclonal antibody) in serous ovarian tumors: Index of proliferative activity with prognostic significance. Gynecol Oncol 56:169-174, 1995
24. Pfisterer J, Wintzer O, Frixen UH, et al: Arc-1/uvomorulin by immunohistochemistry in non-malignant tissue and in ovarian tumours. J Cancer Res Clin Oncol 116:182, 1990 (abstr A2.098.13)
25. Risinger JI, Berchuk A, Kohler MF, et al: Mutations of the E-cadherin gene in human gynecologic cancers. Nat Genet 7:98-102, 1994
26. Veatch AL, Carson LF, Ramakrishnan S: Differential expression of the cell-cell adhesion molecule E-cadherin in ascites and solid human ovarian tumor cells. Int J Cancer 58:393-399, 1994
27. Rimm DL, Sinard JH, Morrow JS: Reduced α-catenin and E-cadherin expression in breast cancer. Lab Invest 72:506-512, 1995
28. Zshiesche W, Schönborn I, Behrens J, et al: Expression of E-cadherin and catenins in invasive mammary carcinomas. Anticancer Res 17:561-568, 1997
29. Ochiai A, Akimoto S, Shimoyama Y, et al: Frequent loss of alpha catenin expression in scirrhous carcinomas with scattered cell growth. Jpn J Cancer Res 85:266-273, 1994
30. Matsui S, Shiozaki H, Inoue M, et al: Immunohistochemical evaluation of alpha-catenin expression in gastric cancer. Virchows Arch 424:375-381, 1994
31. Kozyraki R, Scoazec J-Y, Flejou J-F, et al: Expression of cadherins and α-catenin in primary epithelial tumors of the liver. Gastroenterology 110:1137-1149, 1996
32. Ihara A, Koizumi H, Hashizume R, et al: Expression of epithelial cadherin and alpha- and beta-catenins in nontumoral livers and hepatocellular carcinomas. Hepatology 23:1441-1447, 1996
33. Shimazui T, Schalken JA, Giroldi LA, et al: Prognostic value of cadherin-associated molecules (α-, β- and γ-catenins and p120cas) in bladder tumors. Cancer Res 56:4154-4158, 1996
34. Nakanishi Y, Ochiai A, Akimoto S, et al: Expression of E-cadherin, alpha-catenin, beta-catenin and plakoglobin in esophageal carcinomas and its prognostic significance-immunohistochemical analysis of 96 lesions. Oncology 54:158-165, 1997
35. Oka H, Shiozaki H, Kobayashi K, et al: Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res 53:1696-1701, 1993
36. Colombo N, Chiari S, Maggioni A, et al: Controversial issues in the management of early epithelial ovarian cancer: Conservative surgery and role of adjuvant therapy. Gynecol Oncol 55:47-51, 1994
37. Abrahamson DR: Recent studies on the structure and pathology of basement membranes. J Pathol 149:257-278, 1986
38. Schapers RFM, Pauwels RPE, Havenith MG, et al: Prognostic significance of type IV collagen and laminin immunoreactivity in urothelial carcinomas of the bladder. Cancer 66:2583-2588, 1990
39. Mori M, Shimono R, Kido A, et al: Distribution of basement membrane antigens in human esophagal lesions: An immunohistochemical study. Int J Cancer 47:839-842, 1991
40. Grigioni WF, Garbisa S, D'Errico A, et al: Evaluation of hepatocellular carcinoma aggressiveness by a panel of extracellular matrix antigens. Am J Pathol 138:647-654, 1991
41. Lipponen P, Ji H, Aaltomaa S, et al: Tumour vascularity and basement membrane structure in breast cancer as related tumour histology and prognosis. J Cancer Res Clin Oncol 120:645-650, 1994
42. Campo E, Merino MJ, Tavassoli FA, et al: Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary. Am J Surg Pathol 16:500-507, 1992
43. Tamakoshi K, Kikkawa F, Nawa A, et al: Different pattern of zymography between human gynecologic normal and malignant tissues. Am J Obstet Gynecol 171:478-484, 1994
44. Stenbäck F, Wasenius V: Basement membrane structures in tumors of the ovary. Eur J Obstet Gynecol Reprod Biol 20:357-371, 1985
45. Scher W: Biology of disease. The role of extracellular proteases in cell proliferation and differentiation. Lab Invest 57:607-633, 1987
46. De Nictolis M, Garbisa S, Lucarini G, et al: 72-Kilodalton type IV collagenase, type IV collagen, and Ki 67 antigen in serous tumors of the ovary: A clinicopathologic, immunohistochemical, and serological study. Int J Gynecol Pathol 15:102-109, 1996
47. Muggia FM, Krezorski SK, Hansen H: Cell kinetic studies in patients with small cell carcinoma of the lung. Cancer 34:1683-1690, 1974
48. Schwartz BR, Pinkus G, Bacus S, et al: Cell proliferation in non-Hodgkins lymphoma. Am J Pathol 134:327-336, 1989
49. Cheung ANY: The value of markers for cell proliferation and cell loss in gynecological cancer. Curr Opin Obstet Gynecol 9:32-36, 1997
50. Kuwashima Y, Uehara T, Kurosumi M, et al: Cell dynamics of undifferentiated carcinomas of the ovary. Immunohistochemical estimation of their growth fraction and apoptotic status. Eur J Gynaecol Oncol 16:268-273, 1995
51. Brinkhuis M, Meijer GA, Baak JPA: An evaluation of prognostic factors in advanced ovarian cancer. Eur J Obstet Gynecol Reprod Biol 63:115-124, 1995
52. Omura GA, Brady MF, Homesley HD, et al: Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experience. J Clin Oncol 9:1138-1150, 1991
53. Aure JC, Hoeg K, Kolstad P: Clinical and histologic studies of ovarian carcinoma. Long term follow-up of 990 cases. Obstet Gynecol 37:1-9, 1971
54. Einhorn N, Nilsson B, Sjövall K: Factors influencing survival in carcinoma of the ovary: Study from well defined Swedish population. Cancer 55:2019-2025, 1985
55. Malkasian GD, Decker DG, Webb MJ: Histology of epithelial tumours of the ovary: Clinical usefulness and prognostic significance of histologic classification and grading. Semin Oncol 2:191-201, 1975
56. Sigurdson K, Alm P, Gullberg B: Prognostic factors in malignant epithelial tumors. Gynecol Oncol 15:370-380, 1983
57. Klemi P-J, Pylkkänen L, Kiilholma P, et al: p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 76:1201-1208, 1995
58. Levesque MA, Katsaros D, Yu H, et al: Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 75:1327-1338, 1995